The firm’s 50 day moving average is $0.42 and its 200 day moving average is $0.57. Quoin Pharmaceuticals has a 12-month low of $0.28 and a 12-month high of $1.57. In other news, COO Denise P.
March 04, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan ...
Quoin Pharmaceuticals (QNRX) announced it has filed U.S. and International patent applications for novel topical rapamycin formulations as potential treatments for a number of rare diseases ...
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The ...
Quoin Pharmaceuticals Ltd. has announced the filing of U.S. and International patent applications for new topical formulations of rapamycin aimed at treating rare diseases such as microcystic ...
ASHBURN, Va., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare ...
ASHBURN, Va., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback